Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.29 USD | +4.20% |
|
+2.59% | -35.22% |
06-03 | Oppenheimer Adjusts Immunovant Price Target to $46 From $50, Maintains Outperform Rating | MT |
05-30 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.22% | 3.99B | |
+35.14% | 51.51B | |
-7.43% | 39.03B | |
+35.88% | 38.91B | |
-10.62% | 26.68B | |
+11.63% | 26.13B | |
-17.77% | 19.91B | |
+40.52% | 13.71B | |
+30.70% | 12.38B | |
-3.41% | 11.74B |
- Stock Market
- Equities
- IMVT Stock
- News Immunovant, Inc.
- Goldman Sachs Starts Coverage on Immunovant With Buy Rating, $50 Price Target